ADAMAS PHARMACEUTICALS PRESENTS POSITIVE CLINICAL DATA FOR ADS-5102, A TREATMENT FOR LEVODOPA-INDUCED DYSKINESIA, AT THE WORLD PARKINSON’S CONGRESS
